275 related articles for article (PubMed ID: 37245876)
21. Effectiveness and Safety of Lianhua Qingwen Capsules for COVID-19: A Propensity-Score Matched Cohort Study.
Lu Y; Zhang M; Yang QQ; Li WJ; Yang K; Hu W; Gao SY; Jiang QL; Lin LK; Cheng H; Sun F
Evid Based Complement Alternat Med; 2023; 2023():6028554. PubMed ID: 36846053
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of Lianhua Qingwen Capsule in Treatment of Asymptomatic COVID-19 Patients: A Randomized, Controlled Multicenter Trial.
Zhang L; Wu L; Xu X; Yuan Y; Jiang R; Yan X; Zhang X; Gao Y; Shang H; Hu J; Wang X; Mei J; Wu S; Liu Q
J Integr Complement Med; 2022 Nov; 28(11):887-894. PubMed ID: 36342811
[No Abstract] [Full Text] [Related]
23. Traditional Chinese medicine as an adjunctive therapy for mild and common COVID-19: A systematic review and network meta-analysis.
Wu X; Li W; Qin Z; Xue L; Huang G; Luo Z; Chen Y
Medicine (Baltimore); 2021 Oct; 100(40):e27372. PubMed ID: 34622839
[TBL] [Abstract][Full Text] [Related]
24. Effects of Lianhua Qingwen on Pulmonary Oxidative Lesions Induced by Fine Particulates (PM2.5) in Rats.
Ping F; Li Z; Zhang F; Li D; Han S
Chin Med Sci J; 2016 Nov; 31(4):233-8. PubMed ID: 28065220
[TBL] [Abstract][Full Text] [Related]
25. A meta-analysis for Lianhua Qingwen on the treatment of Coronavirus disease 2019 (COVID-19).
Zhuang J; Dai X; Wu Q; Cai H; Fu X; Zhang W; Chen B
Complement Ther Med; 2021 Aug; 60():102754. PubMed ID: 34153446
[TBL] [Abstract][Full Text] [Related]
26. Effects of four types of integrated Chinese and Western medicines for the treatment of COVID-19 in China: a network meta-analysis.
Jin L; Xu Y; Yuan H
Rev Assoc Med Bras (1992); 2020 Jun; 66(6):771-777. PubMed ID: 32696884
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis.
Hu C; Liang M; Gong F; He B; Zhao D; Zhang G
Evid Based Complement Alternat Med; 2020; 2020():5157089. PubMed ID: 32963563
[TBL] [Abstract][Full Text] [Related]
28. Clinical practice guideline on treating influenza in adult patients with Chinese patent medicines.
Wu L; Chen Y; Ma Y; Yang Z; Yang N; Deng W; Chen Y; Sun Y; Li Y; Lin L
Pharmacol Res; 2020 Oct; 160():105101. PubMed ID: 32739428
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Chinese Medicine Lianhua Qingwen for Treating COVID-19: An Updated meta-Analysis.
Li Y; Xiao P; Liu N; Zhang Z
Front Pharmacol; 2022; 13():888820. PubMed ID: 35721166
[TBL] [Abstract][Full Text] [Related]
30. [Systematic review and Meta-analysis of Lianhua Qingwen preparations combined with Oseltamivir in treatment of influenza].
Yan YM; Yang XJ; Zhao CX; Li ZY; Zhao GZ; Guo YH; Li B; Liu QQ
Zhongguo Zhong Yao Za Zhi; 2022 Aug; 47(15):4238-4247. PubMed ID: 36046914
[TBL] [Abstract][Full Text] [Related]
31. High-quality trials and pharmacological studies needed as translational evidence for the application of traditional Chinese medicine Lianhua Qingwen against COVID-19.
Huang N; Li S
Phytother Res; 2022 Dec; 36(12):4295-4298. PubMed ID: 35915552
[TBL] [Abstract][Full Text] [Related]
32. [Meta-analysis and systematic review of efficacy and safety of Lianhua Qingwen in adjuvant treatment of adult pneumonia].
Lu ZJ; Wu LY; Mou YY; Duan HM; Chen RC; Xiao Y; Zheng WJ
Zhongguo Zhong Yao Za Zhi; 2021 Feb; 46(4):1000-1009. PubMed ID: 33645106
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials.
Liang SB; Fang M; Liang CH; Lan HD; Shen C; Yan LJ; Hu XY; Han M; Robinson N; Liu JP
Complement Ther Med; 2021 Aug; 60():102744. PubMed ID: 34091029
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Lianhua Qingwen for Patients with COVID-19: A Systematic Review and Meta-Analysis.
Sun XH; Zhang S; Yang Z; Chen ZL; Yue SJ; Zhang S; Tang YP
Chin J Integr Med; 2022 Jul; 28(7):650-660. PubMed ID: 35776293
[TBL] [Abstract][Full Text] [Related]
35. Screening for Anti-Inflammation Quality Markers of Lianhua Qingwen Capsule Based on Network Pharmacology, UPLC, and Biological Activity.
Zhou Y; Niu M; Zhang D; Liu Z; Wu Q; Chen J; Zhang H; Zhang P; Pei J
Front Pharmacol; 2021; 12():648439. PubMed ID: 34177573
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of Lianhua Qingwen granule in the treatment of non-influenza viral pneumonia: a randomized, double-blind, placebo-controlled, multicenter clinical study.
Ma C; Chen B; Li Y; Gu L; Dong J; Xu Z; Wei L; He Z; Nie X; Feng S; Cao B; Sun L; Yang L; Li X; Jiang R
Front Med (Lausanne); 2023; 10():1302219. PubMed ID: 38314028
[TBL] [Abstract][Full Text] [Related]
37. Intestinal microbiota analysis and network pharmacology reveal the mechanism by which Lianhua Qingwen capsule improves the immune function of mice infected with influenza A virus.
Xu P; Yang Z; Du S; Hong Z; Zhong S
Front Microbiol; 2022; 13():1035941. PubMed ID: 36504796
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms Underlying the Effects of Lianhua Qingwen on Sepsis-Induced Acute Lung Injury: A Network Pharmacology Approach.
Yang R; Yang H; Wei J; Li W; Yue F; Song Y; He X; Hu K
Front Pharmacol; 2021; 12():717652. PubMed ID: 34721017
[No Abstract] [Full Text] [Related]
39. Comparison study of Beninese and Chinese herbal medicines in treating COVID-19.
Houeze EA; Wang Y; Zhou Q; Zhang H; Wang X
J Ethnopharmacol; 2023 May; 308():116172. PubMed ID: 36773790
[TBL] [Abstract][Full Text] [Related]
40. The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis.
Hu C; He B; Gong F; Liang M; Zhao D; Zhang G
Front Pharmacol; 2022; 13():764774. PubMed ID: 35153773
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
